Author:
Fallowfield Lesley,Payne Heather,Jenkins Valerie
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. [No authors listed.] Prostate cancer mortality in Europe and worldwide. Cancer Research UK
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/mortality#heading-Three
(2016).
2. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
3. Berthold, D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242–245 (2008).
4. Parker, C. C. et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur. Urol. 63, 189–197 (2013).
5. Kantoff, P. & Higano, C. S. Integration of immunotherapy into the management of advanced prostate cancer. Urol. Oncol. 30, S41–S47 (2012).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献